Patents by Inventor Rémy Gébleux

Rémy Gébleux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SORTASE F AND ITS USE IN METHODS FOR CONJUGATION
    Publication number: 20210379196
    Abstract: The present invention relates to a method for producing a conjugate of two substrates, the method comprising the steps of (a) providing two substrates, each substrate being independently selected from the one or more of the groups consisting of small molecules, and proteins, and (b) enzymatically conjugating the two substrates using a sortase F enzyme, or a catalytic domain thereof. One substrate comprises a sortase F recognition motif, while the other substrate comprises at least one motif selected from a Glyn motif, an Alan motif, or a motif consisting of a mixture of Ala and Gly residues the motif totaling n residues, where n is an integer from ?1 to ?21. The reaction takes place in an aqueous reaction medium comprising a salt concentration of from about ?0.01 to ?3 M, thereby producing a conjugated product of the two substrates.
    Type: Application
    Filed: November 4, 2019
    Publication date: December 9, 2021
    Inventors: Ulf GRAWUNDER, Roger BEERLI, Remy GEBLEUX, Chasper PUORGER, Salvatore DI GIROLAMO, Georg LIPPS
  • Non-glycosylated anti-tenascin antibody
    Patent number: 10906963
    Abstract: The present invention relates to variants of the anti-tenascin antibody F16 which are modified to abolish N-glycosylation at positions 88 to 90 in the VL domain. This results in dramatically improved properties, such as improved binding affinity and tumour biodistribution in vivo. Variant F16 antibody molecules and methods for their production and use are provided.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 2, 2021
    Assignee: Philogen S.P.A
    Inventors: Rémy Gébleux, Sarah Wulhfard
  • ANTHRACYCLINE-BASED ANTIBODY DRUG CONJUGATES HAVING HIGH IN VIVO TOLERABILITY
    Publication number: 20210023103
    Abstract: The present invention relates to antibody drug conjugates (ADCs) presenting improved properties of in vivo tolerability.
    Type: Application
    Filed: July 10, 2020
    Publication date: January 28, 2021
    Inventors: Ulf GRAWUNDER, Roger BEERLI, Remy GEBLEUX
  • Anthracycline-based antibody drug conjugates having high in vivo tolerability
    Patent number: 10758556
    Abstract: The present invention relates to antibody drug conjugates (ADCs) presenting improved properties of in vivo tolerability.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: September 1, 2020
    Assignee: NBE-THERAPEUTICS AG
    Inventors: Ulf Grawunder, Roger Beerli, Remy Gebleux
  • ANTHRACYCLINE-BASED ANTIBODY DRUG CONJUGATES HAVING HIGH IN VIVO TOLERABILITY
    Publication number: 20190381079
    Abstract: The present invention relates to antibody drug conjugates (ADCs) presenting improved properties of in vivo tolerability.
    Type: Application
    Filed: August 6, 2019
    Publication date: December 19, 2019
    Inventors: Ulf GRAWUNDER, Roger BEERLI, Remy GEBLEUX
  • Non-Glycosylated Anti-Tenascin Antibody
    Publication number: 20190127451
    Abstract: The present invention relates to variants of the anti-tenascin antibody F16 which are modified to abolish N-glycosylation at positions 88 to 90 in the VL domain. This results in dramatically improved properties, such as improved binding affinity and tumour biodistribution in vivo. Variant F16 antibody molecules and methods for their production and use are provided.
    Type: Application
    Filed: April 12, 2017
    Publication date: May 2, 2019
    Inventors: Rémy Gébleux, Sarah Wulhfard